Pharmacogenomics is expected to be one of the earliest clinical uses of the Human Genome Project, and it will undoubtedly have a significant effect on medical practice. The impact of pharmacogenomics on the drug discovery process, especially drug safety, production, market segmentation, market growth, differentiation, and customized health care, is discussed in this paper. We also go through three obstacles to pharmacogenomics' translation towards clinical practice: reliance on information systems, limited health-care funding, and scientific ambiguity around particular uses of the technology's validation. There is presently no institutional agenda in place to encourage and nurture innovation, create progressive information technology, or secure the funding needed to improve the application of pharmacogenomic techniques in patient care, to our knowledge. Although the promise of these technologies is pushing change in clinical sciences, it is unclear which requirements at the health-care system level will be addressed.